|Titre :||Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone (2021)|
|Auteurs :||B. ROLLAND ; B. TROJAK ; M. NOURREDINE ; J. BACHELLIER ; M. CHAPPUY ; P. BENDIMERAD ; M. KOSIM ; P. HJELMSTROM ; F. MEROUEH ; P. NUBUKPO ; G. BROUSSE|
|Type de document :||Article : Périodique|
|Dans :||Drug and Alcohol Dependence (Vol.220, March 2021)|
|Article en page(s) :||art. 108492|
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASEBUPRENORPHINE ; ETUDE CLINIQUE ; PREFERENCE ; METHADONE ; TRAITEMENT DE MAINTENANCE ; PROFIL SOCIO-DEMOGRAPHIQUE
Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.
Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment.
Results: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring >=7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95% = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95% = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95%CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95%CI = 1.67-7.69) and craving (aOR = 2.38; 95%CI = 1.39-4.02) or improving family (aOR = 1.81; 95%CI = 1.03-3.13) or professional (aOR = 2.22; 95%CI = 1.43-3.85) recovery.
Conclusions: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
• The level of interest in XR-BUP among patients on OAT was high (median score = 7/10).
• The "more interested" participants (=score >=7/10) did not differ on sociodemographics.
• They did not differ either on clinical features (e.g., duration / type of OAT).
• They differed on treatment objectives (more focused on abstinence and recovery).
• They more frequently considered daily intake of oral OAT as a constraint.
|Domaine :||Autres substances / Other substances|
|Affiliation :||Service Universitaire d’Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France|